Drug intelligence / Profile preview

BNT114

Development stage: Phase 1
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

**BNT114** is an investigational mRNA-based cancer vaccine developed by BioNTech SE as part of its FixVac platform, encoding a fixed combination of shared tumor-associated antigens tailored for triple negative breast cancer (TNBC). It employs uridine mRNA-lipoplex formulation for intravenous delivery to stimulate robust CD4+ and CD8+ T-cell responses against patient-specific tumor antigens, aiming to induce anti-tumor immunity. The vaccine was evaluated in a completed Phase 1 first-in-human trial (NCT02316457, TNBC-MERIT) combining it with IVAC_M_uID for individualized neoantigen therapy in patients with TNBC, demonstrating safety and immunogenicity without dose-limiting toxicities.

Other names: IVAC W bre1 uID

Beyond the preview

Go deeper on BNT114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT114.

Explore the full profile